Holen Sie sich die Stockscreener-App
94.01
1.21%
-1.15
Handel nachbörslich:
94.24
0.23
+0.24%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$95.16
Offen:
$95.18
24-Stunden-Volumen:
5.58M
Relative Volume:
1.09
Marktkapitalisierung:
$291.48B
Einnahmen:
$58.07B
Nettoeinkommen (Verlust:
$9.40B
KGV:
31.22
EPS:
3.0113
Netto-Cashflow:
$9.87B
1W Leistung:
+2.26%
1M Leistung:
+2.99%
6M Leistung:
+34.26%
1J Leistung:
+41.20%
1-Tages-Spanne:
$93.22
$95.94
1-Wochen-Bereich:
$89.53
$96.51
52-Wochen-Spanne:
$61.24
$96.51
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
94.01 | 295.05B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
Can AstraZeneca PLC (Common Stock) (ZEGA) stock sustain breakout momentumTrade Ideas & High Accuracy Swing Trade Signals - ulpravda.ru
Can AstraZeneca PLC (ZEG) stock sustain institutional flowsVolume Spike & Technical Buy Zone Confirmations - ulpravda.ru
AstraZeneca Taps Rick Suarez as US President & Head of the US Biopharmaceuticals Business Unit - Contract Pharma
AstraZeneca names insider Rick Suarez as head of US biopharmaceuticals unit - Reuters
AstraZeneca Appoints Rick R. Suarez As Senior Vice President, US President, And Head Of US BioPharmaceuticals Business Unit - MarketScreener
AstraZeneca names Rick Suarez as US president to lead $50 billion investment By Investing.com - Investing.com UK
AstraZeneca plc Announces Executive Changes , Effective March 1, 2026 - MarketScreener
Is It Too Late To Consider AstraZeneca (LSE:AZN) After A 35% One-Year Rally? - Yahoo Finance UK
AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jitters - MSN
Will AstraZeneca PLC (Common Stock) (ZEGA) stock profit from AI boomShort Selling Opportunities & Affordable Market Trading - ulpravda.ru
BostonGene teams up with AstraZeneca on AI-driven oncology - The Pharma Letter
My time working with the manufacturer of the AstraZeneca drug substance - substack.com
BostonGene, AstraZeneca Partner to Advance Oncology Drug Development - Contract Pharma
Check out AstraZeneca PLC's stock price (AZN-GB) in real time - CNBC
Check out AstraZeneca PLC's stock price (AZN) in real time - CNBC
AstraZeneca PLC (AZN) Stock Analysis: A Healthcare Giant With 8% Upside Potential - DirectorsTalk Interviews
AstraZeneca stock hits all-time high at 94.02 USD - Investing.com
AstraZeneca stock hits all-time high at 94.02 USD By Investing.com - Investing.com South Africa
JP Morgan expects solid AstraZeneca quarter and reassuring outlook - Proactive financial news
AstraZeneca's (AZN) Saphnelo Shows Promising Phase III Results - GuruFocus
AstraZeneca's Self-Injectable Lupus Drug Shines In Late-Stage Trial - Benzinga
Astrazeneca Study Shows Saphnelo Injection Reduces Lupus Disease Activity - marketscreener.com
Eyes on Asia: Insilico, Ipsen, AstraZeneca - BioXconomy
AstraZeneca flags positive trial data for Saphnelo as SLE treatment - MarketScreener
Haleon Shares Added, AstraZeneca Removed From Goldman Sachs European Conviction List - AskTraders.com
AstraZeneca says Saphnelo SC showed significant reduction in lupus disease activity - marketscreener.com
G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.
AstraZeneca (AZN) Dropped from Goldman Sachs' European Convictio - GuruFocus
AstraZeneca PLC $AZN Stake Boosted by Allspring Global Investments Holdings LLC - MarketBeat
The Truth About AstraZeneca plc: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Can AstraZeneca PLC ZEG stock sustain institutional flowsMarket Weekly Review & Daily Stock Trend Reports - moha.gov.vn
Key facts: AstraZeneca lowers drug prices for Medicaid; reports share count - TradingView — Track All Markets
AstraZeneca reports total voting rights of 1.55 billion shares - Investing.com
AstraZeneca reports total voting rights of 1.55 billion shares By Investing.com - Investing.com South Africa
Biological Therapies for Cancer Global Markets Report 2025-2030: Merck, BMS, Roche, AstraZeneca, Johnson & Johnson, and Novartis Drive Growth Through Pipeline Expansion and Strategic CollaborationsResearchAndMarkets.com - FinancialContent
Q4 EPS Estimates for AstraZeneca Boosted by Zacks Research - MarketBeat
My Personal CFO LLC Acquires Shares of 38,411 AstraZeneca PLC $AZN - MarketBeat
Zacks Research Raises Earnings Estimates for AstraZeneca - MarketBeat
25,322 Shares in AstraZeneca PLC $AZN Purchased by Moody Lynn & Lieberson LLC - MarketBeat
The Zacks Analyst Blog Highlights Berkshire Hathaway, AstraZeneca, Intel, Kingsway Financial and BK Technologies - Yahoo Finance
Smith Salley Wealth Management Raises Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Top Stock Reports for Berkshire Hathaway, AstraZeneca & Intel - Nasdaq
Ethic Inc. Acquires 11,638 Shares of AstraZeneca PLC $AZN - MarketBeat
Why AstraZeneca PLC (Common Stock) (ZEGA) stock appears on watchlistsHigh Frequency Trading Trends & Free Powerful Profit Generation - bollywoodhelpline.com
Valicenti Advisory Services Inc. Has $4.66 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
DAVENPORT & Co LLC Increases Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (AZN) Stock Price Today - CoinMarketCap
AstraZeneca stock holds steady as mixed news and technicals limit major moves - Traders Union
Robbins Farley Purchases 27,582 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Reaches Settlement With MSN Labs Over Cancer Drug - Bloomberg Law News
Swedbank AB Buys 286,904 Shares of AstraZeneca PLC $AZN - MarketBeat
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):